What molecular properties of ivermectin influence its blood-brain barrier permeability in humans?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Ivermectin is a large, highly lipophilic macrocyclic lactone that, paradoxically, penetrates the mammalian brain poorly under normal conditions because it is a high-affinity substrate for the ATP‑driven efflux transporter P‑glycoprotein (ABCB1/MDR1) at the blood–brain barrier (BBB) and because extensive plasma protein binding limits free drug available for uptake [1] [2] [3]. When P‑glycoprotein function is lost or overwhelmed (genetic loss-of-function, drug–drug inhibitors, overdose, or BBB disruption), brain concentrations rise and neurotoxicity can occur — a conclusion supported by animal knockout models and human case reports [4] [5] [6].
1. Lipophilicity and molecular size: a paradox of passive diffusion versus active exclusion
Ivermectin’s macrocyclic lactone scaffold and predominantly lipophilic composition would predict good passive permeability across lipid membranes, yet multiple reviews and experiments show “unexpectedly poor” BBB penetration for ivermectin, indicating that passive physicochemical favorability is countered in vivo by active transport and binding phenomena [1] [2] [7].
2. P‑glycoprotein (ABCB1/MDR1): the dominant molecular gatekeeper
A large body of cellular, animal and clinical evidence identifies P‑glycoprotein as the principal determinant restricting ivermectin brain entry: Ivermectin is effluxed by P‑gp at the luminal membrane of brain capillary endothelial cells, knockout mice lacking mdr1a/b show dramatically elevated cerebral ivermectin (up to ~90‑fold) and animals or humans with dysfunctional ABCB1 exhibit severe neurotoxicity when exposed to typical or modestly elevated doses [8] [4] [5] [6].
3. Protein binding and plasma availability reduce BBB uptake
High plasma protein binding, notably to albumin, further restricts ivermectin’s brain uptake by lowering the free fraction available to interact with endothelial transporters or diffuse into the CNS; in vitro BBB models showed cellular uptake was strongly inhibited by physiologic albumin concentrations (90% inhibition at 10% albumin in one model) [3].
4. Metabolism, plasma exposure and transporter interactions: indirect molecular influences
Ivermectin is metabolized by hepatic cytochrome P450 enzymes (CYP3A4 among others), so factors that raise systemic concentrations — CYP inhibition, dosage, or formulation differences — increase the likelihood that efflux capacity is saturated and brain exposure rises; co-administered drugs that inhibit P‑gp or CYP pathways can therefore convert a normally excluded molecule into a CNS‑penetrant and toxic one [9] [8].
5. Comparative compounds and transporter selectivity reveal mechanistic nuances
Comparisons with related macrocyclic lactones (e.g., moxidectin, selamectin) show differential BBB transport and safety margins, implying that small differences in molecular structure alter recognition and transport by P‑gp and possibly other carriers, and that other efflux systems such as BCRP appear less relevant for ivermectin at the BBB [5] [4] [10].
6. Clinical evidence, exceptions, and limitations of the record
Clinical experience emphasizes ivermectin’s safety under normal use, attributed to limited BBB penetration via P‑gp, yet serious neurological adverse events have been reported in contexts of overdose, concurrent CNS‑disrupting disease, drug interactions, or rare human ABCB1 nonsense mutations — evidence that the molecular controls can fail in real patients [11] [12] [6]. It must be acknowledged that much mechanistic detail derives from animal, ex vivo, and in vitro studies and from case reports; direct, quantitative measurements of ivermectin permeability across the intact human BBB under variable clinical contexts remain limited in the public literature cited here [8] [2].
Conclusion: the molecular story in one sentence
Ivermectin’s intrinsic lipophilicity and size favor passive entry, but its high plasma protein binding plus active, high‑efficiency efflux by P‑glycoprotein at the BBB are the decisive molecular properties that normally prevent significant human brain penetration; when those defenses are compromised by genetics, co‑drug effects, overdose, or barrier disruption, clinically relevant CNS exposure and toxicity can result [1] [3] [6] [4].